Under a tenth of people who could benefit from GLP-1 drugs including Wegovy are able to get them, caution the World Health Organization as it releases its inaugural advice on the medications.
Given more than one billion individuals worldwide currently classified as obese, it is calling for increased and just access to these injectable treatments.
Based on projections, more than two billion could be obese by 2030 without intervention.
"The new guidelines affirms that obesity is a chronic disease that can be addressed with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are major obstacles to universal availability to the treatments that can help people shift significant body mass, says the body.
Weight-Loss Drug Scarcity
Even in the current most favorable case, the manufacturing of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The guideline urges governments and firms to increase availability, via strategies including patent sharing.
The intellectual property rights on semaglutide – the primary component of a leading brand – is due to expire in multiple countries in 2026.
The Way Obesity Jabs Operate
These medications replicate a natural hormone to delay gastric emptying, curb appetite and boost feelings of fullness so people consume fewer calories.
People usually start to lose weight in the initial weeks of beginning the regular doses.
Studies indicates people may put most of the weight back on a year later of halting the drug, when their usual hunger come back.
Being carrying excess weight elevates your chance for experiencing medical conditions, such as type 2 diabetes, heart disease, stroke, and specific malignancies.
Obesity concerns people in all nations and was linked to 3.7 million fatalities worldwide in 2024, as per the health agency.
